{"id":390761,"date":"2017-12-20T00:00:00","date_gmt":"2017-12-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0011-2017-biopharma-bladder-cancer-unmet-need-us-eu-unneon0011-2017\/"},"modified":"2026-06-28T11:25:30","modified_gmt":"2026-06-28T11:25:30","slug":"unneon0011-2017-biopharma-bladder-cancer-unmet-need-us-eu-unneon0011-2017","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0011-2017-biopharma-bladder-cancer-unmet-need-us-eu-unneon0011-2017\/","title":{"rendered":"Bladder Cancer | Unmet Need | US\/EU | UNNEON0011-2017"},"content":{"rendered":"<p>Treatment of\u00a0unresectable locally advanced or metastatic bladder cancer has remained relatively unchanged since the early 1990s; chemotherapy regimens are still\u00a0the mainstay of treatment. However, following the 2016-2017 <abbr title=\"Food and Drug Administration\">FDA<\/abbr> approvals of the <abbr title=\"programmed death-ligand 1\">PD-L1<\/abbr> inhibitor Tecentriq (Roche\/Genentech) and the <abbr title=\"programmed cell death-1\">PD-1<\/abbr> inhibitor Opdivo (Bristol-Myers Squibb) for platinum-treated patients (i.e., second and later lines), immune checkpoint inhibitors are revolutionizing the treatment algorithm for this indication.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for unresectable locally advanced or metastatic bladder cancer?<\/li>\n<li>What attributes are key influences, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for unresectable locally advanced or metastatic bladder cancer?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in unresectable locally advanced or metastatic bladder cancer?<\/li>\n<li>What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new drug for unresectable locally advanced or metastatic bladder cancer?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60 U.S. and 31 European medical oncologists fielded in January 2017<\/p>\n<p><strong>Key companies:<\/strong> Bristol-Myers Squibb, Eli Lilly, Roche\/Genentech<\/p>\n<p><strong>Key drugs:<\/strong> Tecentriq, Javlor, gemcitabine<\/p>\n","protected":false},"template":"","class_list":["post-390761","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-bladder-cancer","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}